Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase NA 3Phase EARLY_PHASE1 1Phase 4 1Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Cancer Pain 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Terminated × Morphine × Clear all
NCT02078089 2017-01-31

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Indiana University

Phase 1 Terminated
1 enrolled

Cancer Pain, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡